Caladrius Biosciences Statistics Share Statistics Caladrius Biosciences has 7.86M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 7.86M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 6.51M Failed to Deliver (FTD) Shares n/a FTD / Avg. Volume n/a
Short Selling Information Short Interest n/a Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) n/a
Valuation Ratios The PE ratio is -0.47 and the forward
PE ratio is null.
Caladrius Biosciences's PEG ratio is
0.
PE Ratio -0.47 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 0.14 P/FCF Ratio -0.58 PEG Ratio 0
Financial Ratio History Enterprise Valuation Caladrius Biosciences has an Enterprise Value (EV) of -81.98M.
EV / Sales 0 EV / EBITDA 2.83 EV / EBIT 3.69 EV / FCF 3.68
Financial Position The company has a current ratio of 21,
with a Debt / Equity ratio of 0.
Current Ratio 21 Quick Ratio 21 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is -29.85% and Return on Invested Capital is -29.85%.
Return on Equity -29.85% Return on Assets -28.31% Return on Invested Capital -29.85% Revenue Per Employee n/a Profits Per Employee $-1.02M Employee Count 27 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -1.51M Effective Tax Rate 5.2%
Stock Price Statistics The stock price has increased by null% in the
last 52 weeks. The beta is 0.91, so Caladrius Biosciences's
price volatility has been higher than the market average.
Beta 0.91 52-Week Price Change n/a 50-Day Moving Average 0.52 200-Day Moving Average n/a Relative Strength Index (RSI) 28.42 Average Volume (20 Days) n/a
Income Statement
Revenue n/a Gross Profit -29.05M Operating Income -28.97M Net Income -27.47M EBITDA -28.92M EBIT n/a Earnings Per Share (EPS) -1.78
Full Income Statement Balance Sheet The company has 94.97M in cash and 0 in
debt, giving a net cash position of 94.97M.
Cash & Cash Equivalents 94.97M Total Debt n/a Net Cash n/a Retained Earnings -453.02M Total Assets 85.88M Working Capital 71.59M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -22.25M
and capital expenditures -60K, giving a free cash flow of -22.3M.
Operating Cash Flow -22.25M Capital Expenditures -60K Free Cash Flow -22.3M FCF Per Share -1.44
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields CLBS does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield -211.37% FCF Yield -171.65%
Dividend Details Analyst Forecast Currently there are no analyst rating for CLBS.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Sep 15, 2022. It was a
backward
split with a ratio of 1:15.
Last Split Date Sep 15, 2022 Split Type backward Split Ratio 1:15
Scores Altman Z-Score -5.6 Piotroski F-Score 2
